Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy Compared to VYNDAQEL 20 mg Pharmaceutical Investing
Medtronic Launches InPen with Real-Time Guardian Connect CGM Data -- the First Integrated Smart Insulin Pen for People with Diabetes on MDI Medical Device Investing
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update Medical Device Investing
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling Program Medical Device Investing
Bristol Myers Squibb to Participate in Wolfe Research's 2nd Annual Virtual Healthcare Conference Biotech Investing
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹?¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
